Completed PHASE3 INTERVENTIONAL 2-arm NCT01781702

Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients

A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients

Sponsor: Daewon Pharmaceutical Co., Ltd.

Conditions Celebrex Pelubiprofen Rheumatoid Arthritis

Interventions Celebrex 200 mg Pelubiprofen 30 mg

Updated 5 times since 2017 Last updated: Aug 7, 2013 Started: Oct 31, 2010 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01781702, this PHASE3 trial focuses on Celebrex and Pelubiprofen and remains completed. Sponsored by Daewon Pharmaceutical Co., Ltd., it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daewon Pharmaceutical Co., Ltd.

Data source: Daewon Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.